Consultation Wait Time Benchmarks Met, But Delays Seen for Older Children With JIA
Researchers assessed wait times at a single center for patients with juvenile idiopathic arthritis and described factors associated with longer wait times.
Juvenile Idiopathic Arthritis
Gene Polymorphisms in JIA-Associated Uveitis Not Linked to Idiopathic Pediatric Uveitis
Researchers addressed the genetic association between juvenile idiopathic arthritis-associated uveitis and idiopathic pediatric uveitis.
Abatacept Maintains Effective Diphtheria/Tetanus Vaccination Protection in Polyarticular-Course JIA
Researchers assessed protective antibody responses to diphtheria and tetanus vaccination in patients with polyarticular-course juvenile idiopathic arthritis.
Long-Term Registries of Biologic Therapies May Determine Risk for Rare Adverse Events in JIA
Investigators compared long-term safety with regard to rare adverse events between various biologics to treat juvenile idiopathic arthritis.
Tocilizumab May Modify Clinical, Laboratory Features of Macrophage Activation Syndrome in Systemic JIA
Researchers determined the effect of tocilizumab on the clinical and laboratory features of macrophage activation syndrome in patients with complicating systemic juvenile idiopathic arthritis.
Inflammatory Arthritis in Localized Scleroderma May Be Less Likely to Respond to Traditional Therapies
Researchers determined the characteristics of inflammatory arthritis in children with localized scleroderma and their response to treatment regimens.
Validated Prediction Models May Identify Severe Disease Course in Juvenile Idiopathic Arthritis
Researchers validated the performance of a Canadian prediction model in predicting severe disease course and the nonachievement of remission in a Nordic cohort with juvenile idiopathic arthritis.
Preliminary Decision Tree May Help Differentiate Acute Lymphoblastic Leukemia From Juvenile Idiopathic Arthritis
Researchers identified the clinical features that distinguished acute lymphoblastic leukemia from juvenile idiopathic arthritis in children with persistent bone or joint pain for at least 1 month.
Juvenile Idiopathic Arthritis May Be Associated With Increased Gingival Inflammation
Researchers assessed the association between oral health, microbial communities and juvenile idiopathic arthritis.
Methotrexate Injection Approved for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriasis Treatment
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Next post in Pediatric Rheumatology
